deupirfenidone

Small moleculeexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Mar 1, 2020 (NCT04243837)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2026

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetAntioxidant

    antioxidant

Chemistry & pharmacology

Loading structure…

SMILES

[2H]C([2H])([2H])c1ccc(=O)n(-c2ccccc2)c1
Mol. weight
188.24 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07284602Phase 3Apr 30, 2026PureTech
NCT05321420Phase 2Jul 29, 2022PureTech
NCT04652518Phase 2Dec 11, 2020Clinipace LTD, Novotech, PureTech, University of Southern California
NCT04243837Phase 1Mar 1, 2020Novotech, PureTech
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PureTechFor profit4432020
NovotechFor profit2022020
Clinipace LTDFor profit1012020
University of Southern CaliforniaAcademic/Hospital1012020
4 organizations
Page 1 / 1